Findings

What do systematic reviews say?

13 questions · 14 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 6 · 42.9%GRADE not reported 4 · 28.6%Very low 2 · 14.3%Low 1 · 7.1%Moderate 0 · 0%High 1 · 7.1%

Leukotriene receptor antagonist vs placebo

Clinical improvement (continuous) · inactive EoE patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Leukotriene receptor antagonist vs placebo

Histological improvement (dichotomous) · inactive EoE patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Leukotriene receptor antagonist vs placebo

Histological improvement (continuous) · inactive EoE patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Leukotriene receptor antagonist vs placebo

Endoscopic improvement (dichotomous) · inactive EoE patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Leukotriene receptor antagonist vs placebo

Endoscopic improvement (continuous) · inactive EoE patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Leukotriene receptor antagonist vs placebo

Withdrawals due to adverse events · inactive EoE patients

It is very uncertain whether leukotriene receptor antagonist changes withdrawals due to adverse events at 26 weeks compared with placebo (very low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 2.1 [0.21, 21.39]
1 study · 41 participants
Very low

Leukotriene receptor antagonist vs placebo

Clinical improvement (dichotomous) · inactive EoE patients

It is very uncertain whether leukotriene receptor antagonist changes clinical improvement at 26 weeks (dichotomous) compared with placebo (very low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 1.68 [0.66, 4.28]
1 study · 41 participants
Very low

Leukotriene receptor antagonist vs usual care

Exacerbations · autumn asthma exacerbations in children

The review found no eligible studies for this question.

2 findings from 1 review

Interventions for autumn exacerbations of asthma in children 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Interventions for autumn exacerbations of asthma in children 2018 · Cochrane Headline outcomes only
OR 0.5 [0.17, 1.46]
2 studies · 1326 participants
Low

Leukotriene receptor antagonist vs usual care

Adverse events · autumn asthma exacerbations in children

Leukotriene receptor antagonist showed no clear difference in adverse events compared with usual care (high certainty).

1 finding from 1 review

Interventions for autumn exacerbations of asthma in children 2018 · Cochrane Headline outcomes only
OR 0.91 [0.63, 1.32]
2 studies · 1326 participants
High

Leukotriene receptor antagonist vs placebo

Time to resolution of first ulcer (days) · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

Montelukast (leukotriene receptor antagonist; 10 mg daily for 1… led to lower time to resolution of first ulcer (days) compared with placebo; GRADE not reported.

1 finding from 1 review

Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes
2 months
MD -3.95 [-4.38, -3.52]
1 study · 40 participants
GRADE not reported

Leukotriene receptor antagonist vs placebo

Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

1 finding from 1 review

Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes
2 months
The study reported equal drug-related adverse effects for those treated with montelukast and placebo.
1 study · 40 participants
GRADE not reported

Leukotriene receptor antagonist vs placebo

Total number of new lesions over 2-month treatment period · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

Montelukast (leukotriene receptor antagonist; 10 mg daily for 1… led to lower total number of new lesions over 2-month treatment period compared with placebo; GRADE not reported.

1 finding from 1 review

Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes
2 months
MD -3.90 [-4.55, -3.25]
1 study · 40 participants
GRADE not reported

Leukotriene receptor antagonist vs placebo

Pain intensity (0‐10cm visual analogue scale) · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…

Montelukast (leukotriene receptor antagonist; 10 mg daily for 1… led to lower pain (visual analogue scale) compared with placebo; GRADE not reported.

1 finding from 1 review

Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes
2 months
MD -1.15 [-1.46, -0.84]
1 study · 40 participants
GRADE not reported